Next Article in Journal
RETRACTED: Hasanin et al. Exploration of Despair Eccentricities Based on Scale Metrics with Feature Sampling Using a Deep Learning Algorithm. Diagnostics 2022, 12, 2844
Previous Article in Journal
Nevus with Intralymphatic Nevus Cell Protrusion and Lymphatic Invasion
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Systematic Review

Diagnostic Accuracy of Touchscreen-Based Tests for Mild Cognitive Disorders: A Systematic Review and Meta-Analysis

1
Laboratoire d’Informatique Médicale et d’Ingénierie des Connaissances en e-Santé (LIMICS), Université Sorbonne Paris-Nord, 75005 Paris, France
2
Centre Hospitalo-Universitaire de Brest, Université de Bretagne Occidentale, 29200 Brest, France
3
Hôpital Charles Foix, 7 avenue de la République, 94200 Ivry sur Seine, France
4
Faculté de Santé, Sorbonne Université, 91-105 Boulevard de l’Hôpital, 75013 Paris, France
5
Clinical Epidemiology and Ageing (CEpiA) Team, Université Paris Est-Créteil, INSERM, IRMB, 94010 Créteil, France
*
Author to whom correspondence should be addressed.
Diagnostics 2025, 15(18), 2383; https://doi.org/10.3390/diagnostics15182383
Submission received: 31 July 2025 / Revised: 4 September 2025 / Accepted: 10 September 2025 / Published: 18 September 2025
(This article belongs to the Section Clinical Diagnosis and Prognosis)

Abstract

Background/Objectives: Mild neurocognitive disorder (mNCD) is a state of vulnerability, in which individuals exhibit cognitive deficits identified by cognitive testing, which do not interfere with their ability to independently perform in daily activities. New touchscreen tools had to be designed for cognitive assessment and had to be at an advanced stage of development but their clinical relevance is still unclear. We aimed to identify digital tools used in the diagnosis of mNCD and assess the diagnostic performance of these tools. Methods: In a systematic review, we searched 4 databases for articles (PubMed, Embase, Web of science, IEEE Xplore). From 6516 studies retrieved, we included 50 articles in the review in which a touchscreen tool was used to assess cognitive function in older adults. Study quality was assessed using the QUADAS-II scale. Data from 34 articles were appropriate for meta-analysis and were analyzed using the bivariate random-effects method (STATA software version 19). Results: The 50 articles in the review totaled 5974 participants and the 34 in the meta-analysis, 4500 participants. Pooled sensitivity and specificity were 0.81 (95%CI: 0.78 to 0.84) and 0.83 (95%CI: 0.79 to 0.86), respectively. High heterogeneity among the studies led us to examine test performance across key characteristics in a subgroup analysis. Tests that are short and self-administered on a touchscreen tablet perform as well as longer tests administered by an assessor or on a fixed device. Conclusions: Cognitive testing with a touchscreen tablet is appropriate for screening for mNCD. Further studies are needed to determine their clinical utility in screening for mNCD in primary care settings and referral to specialized care. This research received no external funding and is registered with PROSPERO under the number CRD42022358725.

1. Introduction

Mild neurocognitive disorder (mNCD) is a condition in which people experience cognitive difficulties and dysfunction which do not interfere with their ability to independently perform in daily activities. mNCD may be secondary to neurocognitive diseases like Alzheimer’s disease, Parkinson’s disease, vascular dementia, or others. This condition offers a window of opportunity for cognitive stimulation, treatment of symptoms, implementation of compensatory strategies and introduction of healthier lifestyle habits (diet, exercise, etc.) that may delay the onset of a major neurocognitive disorder [1]. Early diagnosis of these conditions is recommended [2], first and foremost for the personal management of the person and their family, but also to enable rapid management by specialized professionals. However, diagnosing mNCD is challenging because coping mechanisms, types of cognitive deficits, and levels of cognitive reserve vary greatly from one individual to another, resulting in considerable variation in patients’ experiences and symptoms and making it difficult to accurately diagnose this condition [2]. The mNCD and its diagnostic criteria were defined by the DSM-5, and these criteria are very close to those for mild cognitive impairment (MCI), a clinical condition very similar to mNCD, which was widely used before the emergence of mNCD [3]. Early diagnosis can also support clinical research and provide a better understanding of the mechanisms of disease progression or enable participation in clinical trials. The purpose of early diagnosis of mNCD is to slow the progression towards major NCD. Although there is no curative treatment at present, there are numerous strategies that can be implemented to prevent the onset of a major NCD, which is not without consequences for the family and caregivers, with the attendant loss of autonomy for the patient [4,5].
The diagnosis of mNCD relies on medical and neuropsychological evaluation performed in memory centers by a specialized team. Diagnostic criteria have evolved, from mild cognitive impairment (MCI), initially including only memory complaints, to mNCD defined by DSM-5 criteria that now encompasses broader cognitive complaints [3,6]. In both definitions, the person exhibits cognitive deficit identified by cognitive tests and retains autonomy in their daily life. The diagnostic process is long and tedious, often with long waiting times before the first appointment, resulting in a loss of opportunity for the patient. mNCD is insidious, and those affected do not always seek medical attention. The general practitioner (GP) is in the front line when it comes to detecting mNCD and referring to specialized centers [7]. It is therefore important to provide accessible and easy-to-use tools for primary care. Detection is not easy for primary care physicians, since no clearly defined strategy exists to identify people at risk and refer them appropriately to a memory center. The most widely used conventional tests are the Mini Mental State Examination (MMSE) [8] and the Montreal Cognitive Assessment (MoCA) [9]. Both are effective in screening for major neurocognitive disorders [10], but they require training and time and are rarely used by general practitioners. In a systematic review, Chun [11] analyzed the screening tools available for MCI and found that the three most frequently used were the MoCA, the MMSE and the Clock Draw Test (CDT). According to their evaluation criteria, the Six Item Cognitive Impairment Test (6 CIT), the MoCA (with thresholds of ≤24/22/19/15.5) and the MMSE (with a threshold of ≤26) as well as the Hong Kong Brief Cognitive Test (HKBC) were the most effective. However, the authors highlighted the lack of evaluation of these new cognitive tools, with threshold values determined according to the populations and environments in which they are used. The performance of the MMSE and MoCA was compared in the meta-analysis by Pinto [10] and their accuracy in identifying mNCDs was found to be 0.780 (95% CI 0.740–0.820) and 0.883 (95% CI 0.855–0.912), respectively. Both tests have been regularly criticized for their threshold values. Thus, there is still progress to be made in identifying patients with mNCD in primary care [2,10].
Tests are progressively digitized to improve objectivity and speed, with the possibility of automated scoring, which would reduce test-taking time and make them more accessible in primary care for GPs [5,12]. In addition, digital tools make it possible to record more detailed results, such as reaction times or pressure on the screen, which are not accessible to a human assessor. Furthermore, touchscreens are more accessible and intuitive thanks to their direct input, compared to keyboard and mouse use [6,13]. In previous work, we showed good detection of major neurocognitive disorders with touchscreens, which is encouraging for primary care [14].
In the present review and meta-analysis, we aimed to investigate the use of touchscreens for screening for mild cognitive disorders comprising mNCD and MCI, in older adults. We also sought to analyze the performance of these tests in relation to the reference diagnosis.

2. Materials and Methods

The protocol was registered with the International Prospective Register of Systematic Review (PROSPERO CRD42022358725), and the report follow the PRISMA-DTA guidelines [15] (see checklist in Supplementary Materials).

2.1. Search Strategy

We searched four databases (Medline, Embase, Web of Science and IEEE Xplore) and included all articles published up to 31 December 2024. The last extraction was in April 2025. We used terms relating to screening or diagnosis, older adults, neurocognitive diseases, touchscreen device (see Table A1 in Appendix A). The search terms were broadened to dementia, but we selected only articles dealing with early stages, taking into account the continuum of neurocognitive diseases from MCI/mNCD to dementia. The search strategies were prepared with the help of an experienced librarian. The reference lists of all articles were manually searched to retrieve relevant studies.

2.2. Article Selection

We included articles whose participants: (i) were over 60 years of age, (ii) were classified according to the presence of mNCD/MCI determined using a conventional assessment of cognition, based on reference diagnostic criteria (Petersen, National Institute on Aging-Alzheimer’s Association; National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s disease and related Disorders Association; Alzheimer’s Disease in neuroimaging initiative, etc.), and (iii) were examined using a novel tool using a digital touchscreen device (tactile tablet, touchscreen computer or smartphone). We did not include studies in which the results for mNCD and M-NCD were mixed and could not be analyzed separately.

2.3. Data Extraction

The first two authors independently selected relevant articles from the results of the queries in PubMed, Embase, Web of Science and IEEE Xplore. Any discrepancies were discussed among evaluators until consensus was reached. A third author was consulted in case of disagreement. Reference lists were managed using Zotero® (version 6.0.30) and Excel 2013®. Duplicates were individually checked by the two authors. Each investigator evaluated the study selection criteria independently. Reasons for exclusion were noted in Zotero and differences were resolved by discussion.
Descriptive data for each article were collected by two authors and included the descriptive characteristics of the studies, namely: country, year of publication, period of inclusion of participants, mean age of population, reference diagnostic criteria, neuropsychological tests for reference diagnosis. We also recorded the characteristics of the touchscreen test, namely: name of the new test, mode of administration (self-administered or interviewer-administered), cognitive functions assessed, duration of the new test. Sensitivity, specificity and contingency tables were also included for performance analysis in the meta-analysis. If data were missing or unclear to both investigators, they were recorded as “not specified” (NS) in the table. When the contingency table was not included in the original article, we contacted the authors to obtain it, and in the absence of a reply, we calculated the number of true positives, false positives, true negatives and false negatives with sensitivity and specificity from available data.

2.4. Quality Assessment

The quality of the included articles was assessed by two authors (NUD, FM) using the Quality Assessment of Diagnostic Accuracy Studies 2 instrument (QUADAS-2) [16] which measures the risk of bias and applicability of diagnostic accuracy studies. It comprises four key domains: patient selection, index test, reference standard, flow and timing. Each domain is considered for its risk of bias and applicability, and judged as high, low or unclear.
There are no official or validated decision rules for determining whether a study is of good or poor quality. We chose to exclude articles that were not of sufficiently high quality, and for this purpose, we defined our own decision rule, namely exclusion of studies with: 2 high risks of bias; or 2 high applicability concerns; or 3 risks of unclear bias; or 2 unclear applicability concerns; or 1 unclear applicability concern and 1 high applicability concern.

2.5. Meta-Analysis

We sought to complement the information about the performance of the tools tested. To this end, we collected information on true positives, false positives, true negatives and false negatives. If the information did not appear in an article, we contacted the corresponding author to obtain it.
Meta-analysis was performed with the METADTA program [17] in STATA software (version 19), which uses the bivariate random-effects method. Inter-study heterogeneity was assessed by the I2 coefficient. We performed subgroup analyses according to the type of touchscreen used (touchscreen computer or touchscreen tablet), ease of transport (fixed or mobile device), type of questionnaire administration (rater-administered or self-administered), and test duration (brief test lasting less than 10 min, and longer test lasting more than 10 min).

3. Results

3.1. Studies Included

The database query yielded 6516 articles. After removal of duplicates and exclusions, 181 articles remained to be evaluated for eligibility. After the QUADAS-2 assessment, we finally included 50 studies in the review and 34 articles in the meta-analysis (Figure 1).

3.2. Study Characteristics

We included 50 articles in the systematic review. The characteristics of the included studies are presented in Appendix A. The results are presented in 2 tables according to the digital device used, namely studies using a tactile tablet (Table A2), and studies using a computer touchscreen (Table A3). Articles were published between 2005 [18] and 2024 [19] and were performed in 17 countries located in Europe, Asia, North America and South America.

3.2.1. Participants and Settings

The studies involved 5974 participants (3368 women and 2255 men) (4 studies did not mention the participants’ sex). The number of participants by study varied from 12 [20] to 524 [21] with an average of 119. Mean age of participants was 72 years, and ranged from 53 to 81 years [22,23]. The recruitment was performed in memory centers (n = 27), in the community (n = 8), in both memory centers and the community (n = 3), hospitals (n = 14), daycare centers (n = 3), health institutions (n = 5), memory clinic and research registry (n = 2), memory clinic, research registry and community (n = 3), hospital, agencies or community advertisements (n = 2), hospital, retirement home and community (n = 1), nursing home and association (n = 1), GP offices and community (n = 1), and from a demographic surveillance record (n = 1). Three studies did not specify their recruitment methods.

3.2.2. Reference Diagnosis

The reference diagnosis of mNCD/MCI was determined by specialized professionals using reference criteria and tests or parts of tests validated and accepted by the scientific community and are detailed in Appendix A (Table A2 and Table A3). The reference diagnosis was considered as that established by a team of specialists in their own clinic, using official criteria. The studies used diagnostic criteria specific to their usual practice: Petersen’s criteria (n = 24), the National Institute on Aging and Alzheimer’s Association (NIA-AA) criteria (n = 5), the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer’s Disease and Related Disorders Association (NINCDS/ADRDA) criteria (n = 4), Jak’s criteria (n = 1), the National Alzheimer’s Coordinating Center (NACC) criteria (n = 1), the American Academy of Neurology (AAN) criteria (n = 1), the DSM 5 criteria (n = 1), ADI criteria (n = 1), NIA-AA and DSM-5 criteria (n = 1), Alzheimer’s Disease Neuroimaging Initiative (ADNI) criteria (n = 1), Alzheimer’s Disease Research Centers (ADRC) criteria (n = 1), and international working group criteria (n = 1). Eight studies did not specify diagnostic criteria but reported that a diagnosis was made following a comprehensive medical and neuropsychological evaluation. A sensitivity analysis was carried out to compare the 24 studies using Petersen’s criteria for MCI with the others, and we found no difference between them (see Figure A1 in Appendix A).

3.2.3. Touchscreen Test Procedures

A phase of learning and familiarization with the digital tool was mentioned in 16 studies and was not specified in the others.
Digital test times ranged from 2 min [24] to 2.5 h [25], 13 studies did not specify the duration and one study did not record the test duration [26]. The time needed to complete the tests was less than 5 min in 8 studies, between 10 and 15 min for 7 studies, between 15 and 30 min for 12 studies, between 30 and 60 min for 6 studies and more than an hour in 3 studies.
Thirty-one studies used a self-administered assessment (62%), 13 were assessor-administered (26%) and 6 studies (12%) did not report this information. The professionals involved were health practitioners or researchers trained in the assessments required.
The studies used tactile tablets (n = 34) and touchscreen computers (n = 16).
Forty of these devices were mobile (80%) versus 6 fixed (12%), while 4 studies did not specify the characteristics of their tool (8%).

3.2.4. Performance Results

Thirty-four studies measured the performance of their digital tests by calculating the sensitivity and specificity of their conclusion compared to the reference diagnosis. Sensitivity ranged from 0.41 (95%CI: 0.21 to 0.64) to 1.00 (95%CI: 0.74 to 1.00) [27,28]. Specificity ranged from 0.56 (95%CI: 0.28 to 0.85) to 1.00 (95%CI: 0.80 to 1.00) [26,28].

3.3. Quality Assessment

Overall, the quality of the studies assessed by QUADAS-2 was quite good [18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79] (Table A4 in Appendix A). We excluded 13 studies based on our decision rule.

3.4. Meta-Analysis

3.4.1. Main Results

We included 34 articles in the meta-analysis, totaling 4500 participants. Pooled sensitivity and specificity were 0.81 (95%CI: 0.78 to 0.84) and 0.83 (95%CI: 0.79 to 0.86), respectively (Figure 2). The positive likelihood ratio (LR+) was 4.71 (95%CI: 3.88 to 5.73), the negative likelihood ratio (LR-) was 0.23 (95%CI: 0.19 to 0.27), and the diagnostic odds ratio (DOR) was 20.55 (95%CI: 14.66 to 28.80). The summary ROC curve indicated a high overall discriminative performance of the tests, with a summary point near the upper-left corner of the ROC space and reasonably narrow confidence region (Figure 3). I2 coefficient was 56.2, indicating that the studies were quite heterogenous.

3.4.2. Subgroup Analysis

We analyzed the performance of the tests according to their procedures and device characteristics (duration, type of administration, type of touchscreen and mobility of the device) using the chi-2 test. Pooled sensitivity and specificity of these subgroups are presented in Figure 4 and the corresponding forest plots with the individual studies are shown in Appendix A (Figure A2, Figure A3, Figure A4 and Figure A5) and sections below.
Duration: Brief Test vs. Longer Test
Sensitivity and specificity in studies using brief tests (0.79; 95%CI: 0.73 to 0.84 and 0.83; 95%CI: 0.76 to 0.88, respectively) were not significantly different from those of studies using longer tests (0.82; 95%CI: 0.77 to 0.86, p = 0.68, and 0.84; 95%CI: 0.79 to 0.88, p = 0.83) (Figure A2).
Type of Administration: Self or Assessor Administered
Sensitivity and specificity in studies using assessor-administered tests (0.81; 95%CI: 0.76 to 0.85 and 0.83; 95%CI: 0.78 to 0.87, respectively) were not significantly different compared to those using self-administered tests (0.81; 95%CI: 0.75 to 0.86, p = 0.79, and 0.83; 95%CI: 0.77 to 0.88, p = 0.08) (Figure A3).
Mobility: Fixed or Mobile Device
Sensitivity in studies using a mobile device were not significantly different from that of studies using a fixed device (0.82; 95%CI: 0.78 to 0.85 and 0.78; 95%CI: 0.66 to 0.86, p = 0.43). Conversely, specificity in studies using a mobile device was significantly different higher than in studies using a fixed device (0.85; 95%CI: 0.82 to 0.88 and 0.75; 95%CI: 0.65 to 0.84, p = 0.04) (Figure A4).
Type of Interface: Touchscreen Computer or Tactile Tablet
Sensitivity and specificity in studies using a tactile tablet (0.81; 95%CI: 0.76 to 0.84 and 0.83; 95%CI: 0.79 to 0.87, p = 0.71) were not significantly different from those of studies using a touchscreen computer (0.82; 95%CI: 0.76 to 0.87, and 0.82; 95%CI: 0.76 to 0.87, p = 0.68) (Figure A5).
The cognitive tests with the highest combined sensitivity and specificity are summarized in the table below (Table 1).

4. Discussion

This review and meta-analysis showed that cognitive tests on touchscreen tools are appropriate to diagnose mNCD in older adults. A large variety of digital devices give satisfactory results in screening for mNCD/MCI. Although imperfect, the overall performance of touchscreen cognitive tests is similar to that of the MoCA, the reference clinical test to screen for mNCD, and several touchscreen cognitive tests outperformed it. However, the heterogeneity of methods and tools makes it difficult to compare studies, precluding any conclusion as to which one is the most effective.
The high degree of heterogeneity among the studies led us to examine test performance based on their main characteristics in a subgroup analysis. It is interesting to note that tests that are short, self-administered and conducted on a touchscreen tablet perform as well as longer tests administered by an assessor or on a fixed device. The former characteristics are very appealing for devices in clinical use, as they are simple, require little professional time and can be used on easily accessible systems.
Through our review, several tools appeared to us to be attractive, due to their good performance in diagnosing mild cognitive disorders (Table 1). Rodríguez-Salgado [54] developed the tool that combines the most practical clinical features and performance, namely the Brain Health Assessment (BHA). It consists of 4 tests: Favorites (associative memory), Match (processing speed and executive function), Line Orientation (visuospatial skills), and Animal Fluency (language). It is a brief, tablet-based cognitive battery validated in English and Spanish, administered by an assessor. Garre-Olmo [28] reported very good results in terms of sensitivity and specificity for the detection of MCI with the Cambridge Cognitive Examination Revised (CAM-COG-R). This is part of a bigger test and consists of 7 tasks assessing cognitive, kinesthetic, visuospatial and motor features on a touchscreen tablet. It can be obtained by purchasing the CAMDEX-DS-II (A Comprehensive Assessment for Dementia in People with Down Syndrome and Others with Intellectual Disabilities) and is available in English and Dutch. The current version is administered by a professional. Park worked on a promising application that revealed the particularities of people with cognitive impairments in their daily use of the telephone keypad [80]. One might imagine downloading this module, which would evaluate keyboard use over several hours or days, taking much of the stress out of traditional exams. Another approach is home assessment, as tested by Thompson with the Mobile Monitoring of Cognitive Change (M2C2) [81], which measures visual working memory, processing speed and episodic memory. The M2C2 is a self-administered test, performed completely remotely, and the episodic memory task demonstrated good ability to distinguish Aß PET status among study participants.
This systematic review and meta-analysis have several limitations. First, it is likely to be affected by publication bias, as studies with null or negative results may be underrepresented. In addition, patient selection in the included studies limits generalizability. Indeed, many of the studies recruited highly selected or convenience samples, which may inflate performance estimates. The predominance of case–control study designs also introduces selection biases that could overestimate diagnostic accuracy compared to prospective cohort study designs. In order to limit potential bias, we excluded 13 articles that we rated, on an ad hoc basis, as having a high risk of bias according to the QUADAS-2 scale, which may also be considered a limitation of our meta-analysis. We also encountered some difficulties with the term “touchscreen device”, which is broad and unclear, as pointed out in Nurgalieva’s review about touchscreen devices. Indeed, devices are not often described in detail, and technology has undergone rapid development in recent years [82]. To address this challenge, we include several terms in our search equation intended to obtain a broad selection of articles and render our screening sensitive (see Table A1 in Appendix A). Nurgalieva’s review also highlights the heterogeneity of older people, and the need to categorize them according to the sensory or cognitive limitations they encounter, in order to be able to propose adapted tools.

5. Conclusions

Touchscreen devices can be used to detect mNCD, but their development has yet to be validated by real-life studies. Further efforts are warranted to harmonize assessment methods, although initial results are promising.
In future works, there should be methods for standardizing test procedures so that tools can be compared more easily. It would be of interest for clinical studies to describe their methods accurately and in detail, as well as the manner in which the formal diagnosis was made, in order to fully understand what is being evaluated. Results relating to tool performance are important for the purposes of comparison and should be published in all articles. Touchscreen-based tools need to be evaluated in real-life conditions with people being diagnosed with cognitive disorders, and the results compared.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/diagnostics15182383/s1. Reference [83] is cited in the supplementary materials.

Author Contributions

Conceptualization, J.B., S.P. and N.U.D.; methodology, J.B., N.U.D., C.L.-L. and F.M.; validation, J.B.; formal analysis, J.B., C.L.-L. and N.U.D.; investigation, N.U.D., F.M. and B.O.; data curation, N.U.D. and F.M.; writing—original draft preparation, N.U.D. and B.O.; writing—review and editing, J.B.; supervision, J.B. and S.P.; project administration, F.B. and J.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The original contributions presented in this study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Acknowledgments

The authors would like to thank Stéphanie Lamy, at Université Sorbonne Paris Nord for her support on the article search and Fiona Ecarnot (Université Marie & Louis Pasteur, Besançon, France) for proofreading the manuscript.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
MCIMild Cognitive Impairment
NCDNeuro Cognitive Disorder
NINCDS-ADRDANational Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association
NIAAANational Institute on Aging-Alzheimer’s Association
MoCAMontreal Cognitive Assessment
MMSEMini Mental State Examination

Appendix A

Table A1. MeSH terms used for the database query.
Table A1. MeSH terms used for the database query.
ThemesMeSH Terms
Age factorelderly, elder, aged, older adult, geriatrics
Screening/diagnosticDiagnosis, diagnose, screening, assessment, evaluation, testing, detection
Neurocognitive
condition
neurodegenerative diseases, cognitive disorders, neurocognitive disorders, dementia, Alzheimer disease
Touchscreen
device
handheld computer, numeric tablet, smartphone, mobile applications, cell phone, touch screen, computer device, mobile technology, computer, electronic device, tablet, tablet computer, mobile device, web app
Table A2. Characteristics of studies using a tactile tablet or smartphone.
Table A2. Characteristics of studies using a tactile tablet or smartphone.
Author Year, CountryParticipants
n (age ± SD)
Name of the Touchscreen Test
Language
Functions AssessedSelf-AdministrationTouchscreen Test DurationMobilityReference Diagnostic CriteriaNeuropsychological Testing for Reference Diagnosis
Alegret 2020 [29], Spain 61 MCI (67.74 ± 7.93)
154 control (67.98 ± 7.92)
FACEmemory®
Spanish
Memory, recognitionyes30yesNINCDS/ADRDA NS
An 2024 [76],
Korea
126 MCI (70.2 ± 7.8)
55 SCD (69.7 ± 7.2)
Seoul Digital Cognitive Test
Korean
Memory, attention, language, visuospatialNS30yesPetersenSNSB-II
Berron 2024 [84],
Germany and USA
25 MCI (69.2 ± 6.8)
78 control (68.2 ± 5.5)
Remote Digital Memory Composite
English and German
Memory, discrimination, RecognitionyesNSyesNINCDS/ADRDA MMSE, CERAD and neuropsychological battery tests
Boz 2019 [31],
Turkey
37 MCI (70.4 ± 7.3)
52 control (67.6 ± 6.0)
Virtual Supermarket
Turkish
Visual and verbal memory, executive function, attention, spatial navigationno25yesPetersen MMSE and neuropsychological battery tests
Cheah 2022 [34],
Taïwan
59 MCI (67.5 ± 6.3)
59 control (62.6 ± 5.9)
Rey-Osterrieth Complex Figure
Taiwanese
Visuospatial, memory, organization skills, attention, visuomotor coordinationnoNSyesJak et al.Rey-Osterrieth Complex Figure (paper)
Chin 2020 [35],
Korea
42 MCI (71.7 ± 7.3)
26 control (68.5 ± 6.3)
Inbrain Cognitive Screening Test
Korean
Attention, language, visuospatial, memory and executive functionyes30yesPetersenMMSE and Seoul Neuropsychological Screening Battery
Freedman 2018 [37], Canada50 MCI
57 control
Toronto Cognitive Assessment
English
Memory, orientation, visuospatial, attention, executive control, languageno34yesNIA-AANeuropsychological battery tests
Garre-Olmo 2017 [28], Spain12 MCI (63.5 ± 6.5)
17 control (70.2 ± 7.4)
7 tasks
Spanish
Cognitive, kinesthetic, visuospatial, motor featuresno10–15yesPetersenCambridge Cognitive Examination Revised
Gielis 2021 [39],
Belgium
23 MCI (80.0 ± 5.2)
23 control (70.0 ± 5.4)
Klondike Solitaire
Dutch
Cognitive skills, spatial and temporal functionyes79yesPetersenMoCA, MMSE and CDR
Ishikawa 2019 [27],
Japan
25 MCI (75.9 ± 5.3)
36 control (70.0 ± 5.0)
Five drawing tasks
Japanese
Memory, visuospatial, executive functionnoNSyesPetersenMMSE
Kobayashi 2022 [43], Japan65 MCI (74.5 ± 4.9)
52 control (72.6 ± 3.8)
Five drawing tasks
Japanese
Memory, visuospatial, executive functionyesNSyesNIA-AAMMSE and neuropsychological battery tests
Kubota 2017 [20],
USA
4 MCI
6 control
Virtual Kitchen Challenge
English
Executive function, memory, attention, processing speedyesNSyesNSNeuropsychological battery tests
Li 2025 [77],
China
93 MCI (73.1 ± 4.8)
88 control (72.2 ± 5.1)
BrainNursing
Chinese
Memory, language, attention, visuospatial, executive and fine motor functionsyes25yesNSMoCA, MMSE and a neuropsychological battery test
Li 2024 [74],
China
108 MCI (71.3 ± 4.5)
99 control (70.1 ± 4.0)
Drawing and Dragging Tasks
Chinese
Memory, attention, orientation, visuospatial, hand motor performanceyes15yesNINDS-ADRDAMoCA, MMSE and a neuropsychological battery test
Li 2023 [44],
China
61 MCI (71.0 ± 5.8)
59 control (67.9 ± 6.2)
Digital cognitive tests + data from a smartwatch
Chinese
Verbal fluency, memory, attention, listening, visuospatial and executive functionyesNSyesPetersenMMSE and MoCA
Li 2023 [45],
China
30 MCI (69.2 ± 5.9)
30 control (66.1 ± 7.9)
Fingertip interaction handwriting digital evaluation
Chinese
Memory, orientation, optimal decision-making, fingertip executive dynamic abilitiesnoNSyesNIA-AAMMSE
Li 2022 [26],
China
43 MCI (61.9 ± 9.6)
12 control (58.3 ± 14.6)
Tree drawing test
Chinese
Feature extraction of the drawingyesNSyesNSMMSE
Libon 2025 [19],
USA
17 MCI (74.8 ± 7.1)
23 control (70.0 ± 8.7)
Digital neuropsychological protocol
English
Memory, executive function, languageyes10yesNSNeuropsychological battery tests
Müller 2019 [47],
Germany
138 MCI (70.8 ± 8.4)
137 control (69.6 ± 7.8)
Digital Clock Drawing Test
German
Visual perception and encoding, attention, anticipatory thinking, motor planning and executive functionsNS4yesPetersen CERAD
Müller 2017 [48],
Germany
30 MCI (65.3 ± 6.6)
20 control (66.9 ± 9.4)
Digitizing visuospatial construction task
German
Visuospatial construction, movements kinematics, fine motor control, coordinationyes<1yesPetersen and NIA-AACERAD (German)
Na 2023 [49],
Korea
93 MCI
73 control
Inbrain Cognitive Screening Test
Korean
Visuospatial skills, attention, memory, language, orientation, executive functionyesNSyesPetersenCERAD (Korean)
Rigby 2024 [78],
USA
62 MCI (72.1 ± 6.8)
96 control (69.0 ± 6.4)
NIH Toolbox Cognition Battery
English and Spanish
Memory, executive function, processing speedno30yesNACCNational Alzheimer’s Coordinating Center Unified Data set version 3
Robens 2019 [53],
Germany
64 MCI (67.9 ± 11.2)
67 control (65.9 ± 10.3)
Digitized Tree Drawing Test
German
Visuospatial and planning abilities, semantic memory and mental imagingyes4yesPetersen and McKhanCERAD (German) and Clock Drawing test
Rodríguez-Salgado 2021 [54],
Cuba
46 MCI (72.7 ± 7.5)
53 control (70.4 ± 5.9)
Brain Health Assessment
Cuban-Spanish
Memory, processing speed, executive function, visuospatial skills, languageyes10yesNSMoCA, CERAD, BHA and neuropsychological battery tests
Simfukwe 2022 [22],
Korea
22 MCI (67.2 ± 6.0)
22 control (53.0 ± 1.5)
Digital Trail Making Test-Black and White
English and Korean
Attention, mental flexibility, visual scanningyes5yesNSTrail Making Test-Black and White
Sloane 2022 [58],
USA
21 MCI (71.1)
65 control (70.2)
Miro Health
English
Movements, speech, languageyes5 to 60yesAmerican Academy of NeurologyMMSE, Telephone Interview for Cognitive Status; Geriatric Depression Scale
Suzumura 2018 [59],
Japan
15 MCI (74.3 ± 6.0)
48 control (73.6 ± 8.3)
JustTouch screen
Japanese
Finger motor skillsyesNSyesPetersenMMSE
Um Din 2024 [72],
France
49 mNCD (79.5 ± 6.0)
47 control (78.2 ± 8.5)
Digital Clock Drawing Test
French
Visuospatial, memory, planificationno5yesDSM-VNeuropsychological battery tests and paper CDT
Wu 2023 [63],
China
73 MCI
175 control
Efficient Online MCI Screening System
Chinese
Memory, attention, flexibility, visuospatial and executive function, cognitive proceeding speedyes10yesPetersen and American Academy of NeurologyMoCA-C, IADL, AD8 questionnaire
Yamada 2022 [65],
Japan
67 MCI (74.1 ± 4.5)
46 control (72.3 ± 3.9)
Five drawing tasks
Japanese
Visuospatial, planificationyesNSyesMcKhann, McKeith and PetersenMMSE
Ye 2022 [66],
USA
22 MCI (73.5 ± 5.9)
35 control (67.8 ± 9.6)
BrainCheck battery V4.0.0
English
Memory, inhibition, attention, flexibilityyes15 to 37yesAlzheimer’s Disease InternationalNeuropsychological battery tests
Yu 2019 [71],
Taiwan
14 MCI (74.9 ± 5.2)
18 control (75.8 ± 5.8)
Graphomotor tasks: two graphic and two handwriting tasks
Chinese
Fine motor functionnoNSyesPetersenCDR and neuropsychological battery tests
Zhang 2024 [75],
China
38 MCI (67.5 ± 7.2)
26 control (64.6 ± 7.0)
Tablet’s Geriatric Complex Figure Test
Chinese
Memory, visuospatial, planning, attention, fine motor coordinationno23yesNIA-AANeuropsychological battery tests
Zygouris 2015 [68],
Greece
34 MCI (70.3 ± 1.2)
21 control (66.6 ± 1.2)
Virtual Supermarket Test
Greek
Memory, executive function, attention, spatial navigationno10yesPetersenMoCA and MMSE
Zygouris 2020 [69],
Greece
47 MCI (67.9 ± 0.8)
48 SCD (66.0 ± 0.6)
Virtual Supermarket Test
Greek
Visual and verbal memory, executive function, attention, spatial navigationyes30yesPetersenMMSE, MoCA
NS: not specified; SCD: Subjective Cognitive Decline. NIA-AA: National Institute on Aging-Alzheimer’s Association; NINCDS-ADRDA: National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s disease and related Disorders Association; NACC: National Alzheimer’s Coordinating Center; MoCA: Montreal Cognitive Assessment; CERAD: Consortium to Establish a Registry for Alzheimer’s Disease neuropsychological test battery; CDT: Clock Drawing Test; SNSB: Seoul Neuropsychological Screening Battery.
Table A3. Characteristics of the studies using a computer touchscreen.
Table A3. Characteristics of the studies using a computer touchscreen.
Author Year,
Country
Participants
n (age ± SD)
Name of the Touchscreen Test
Language
Functions AssessedSelf-AdministrationTouchscreen Test DurationMobilityReference Diagnostic CriteriaNeuropsychological Testing for Reference Diagnosis
Ahmed 2012 [23],
England
15 MCI (80.9 ± 7.2)
20 control (77.4 ± 4.0)
Computer-Administered Neuropsychological Screen for Mild Cognitive Impairment
English
Memory, language, executive functionsyes30noPetersenACE-R, MoCA
Cabinio 2020 [32],
Italy
32 MCI (76.7 ± 5.3)
107 control (76.5 ± 3.0)
The Smart Aging Serious Game
Italian
Executive function, attention, memory and orientationyesNSNSNIA-AA, DSM-5MoCA, FCSRT, TMT A&B
Curiel 2016 [36],
USA
34 MCI (77.6 ± 6.3)
64 control (74.0 ± 7.3)
The Smart Aging Serious Game
English
Memory, categorizationNS10NSNSMMSE and the Loewenstein-Acevedo Scales for Semantic Interference and Learning
Fukui 2015 [38],
Japan
41 MCI (75.3 ± 6.5)
75 control (75.1 ± 6.1)
Touch-panel screening test: flipping cards, finding mistakes, arranging pictures and beating evils
Japanese
Memory, attention and discrimination, memory, judgmentNSNSnoADNIMMSE, HDS-R
Inoue 2005 [18],
Japan
22 MCI (72.0 ± 9.6)
55 control (72.6 ± 7.3)
Six tests: age and year of birth, 3 words memory test, time orientation test, 2 modified delayed-recall test, visual working memory test
Japanese
Memory, orientation, visual working memoryyes5noPetersenNeuropsychological tests, neuroimaging examination and medical checks
Isernia 2021 [41],
Italy
60 MCI (74.2 ± 5.0)
74 control (75.5 ± 2.7)
Smart Aging Serious Game: 5 tasks of functional activities of everyday life
Italian
Memory, spatial orientation, executive functions, attentionyes30NSNINCDS-ADRDAMoCA and neuropsychological battery
Liu 2023 [73],
China
74 MCI (66.3 ± 10.1)Computerized cognitive training
Chinese
Memory, attention, perception, executive functionNSNSNSPetersenMoCA, MMSE, CDR
Memória 2014 [46],
Brasil
35 MCI (73.8 ± 5.5)
41 control (71.7 ± 4.6)
Computer-Administered Neuropsychological Screen for Mild Cognitive Impairment
Portuguese
Executive function, language, memoryyes30–50NSPetersenMoCA
Noguchi-Shinohara 2020 [50],
Japan
94 MCI (75.8 ± 4.1)
100 control (75.0 ± 3.2)
Computerized assessment battery for Cognition
Japanese
Time orientation, recognition, memoryyes5noInternational Working GroupMMSE
Park 2018 [51],
Korea
74 MCI (74.4 ± 6.5)
103 control (74.9 ± 7.0)
Mobile cognitive function test system for screening mild cognitive impairment
English and Korean
Orientation, memory, attention, visuospatial ability, language, executive function, reaction timeno10yesPetersenMoCA-K
Porrselvi 2022 [25],
India
18 MCI (71.0 ± 5.4)
100 control (66.3 ± 7.8)
Tamil
computer-assisted cognitive test Battery
Tamil
Attention, memory, language, visuospatial skills and spatial cognition, executive function, processing speedNS150yesPetersenMoCA, CDR Scale, MMSE, and neuropsychological battery
Saxton 2009 [21],
USA
228 MCI (75.2 ± 6.8)
296 control (71.8 ± 5.9)
Computer Assessment of Mild Cognitive Impairment
English
Memory verbal and visual, attention, psychomotor speed, language, spatial and executive functioningyes20yesCriteria of the University of Pittsburgh Alzheimer Disease Research (ADRC)MMSE and neuropsychological battery
Wang 2023 [24],
China
46 MCI (70.0)
46 control (68.0)
Smart 2-Min Mobile Alerting Method
Chinese
Fingertip interaction, spatial navigation, executive processno2yesNIA-AAMMSE
Wong 2017 [62],
China
59 MCI (78.2 ± 8.1)
101 control (70.5 ± 8.6)
Computerized Cognitive Screen
English
Memory, executive functions, orientation, attention and working memoryyes15noNSMoCA
Wu 2017 [64],
France
129 MCI (76.5 ± 7.5)
112 control (74.7 ± 6.9)
Tablet-based cancelation test
French
Attention, visuospatial, psychomotor speed, fine motor coordinationyes3yesPetersenK-T cancelation test
NS: not specified. NIA-AA: National Institute on Aging-Alzheimer’s Association; NINCDS-ADRDA: National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s disease and related Disorders Association; ADNI: Alzheimer’s Disease in neuroimaging initiative; CDR: Clinical Dementia Rating Scale.
Figure A1. Analysis of sensitivity of studies using Petersen’s MCI criteria with others [18,21,23,27,28,29,31,32,34,35,37,38,41,43,46,47,48,50,51,53,63,64,65,66,68,69,72,74,75,76].
Figure A1. Analysis of sensitivity of studies using Petersen’s MCI criteria with others [18,21,23,27,28,29,31,32,34,35,37,38,41,43,46,47,48,50,51,53,63,64,65,66,68,69,72,74,75,76].
Diagnostics 15 02383 g0a1
Table A4. Results of the quality assessment of the articles by the QUADAS-2.
Table A4. Results of the quality assessment of the articles by the QUADAS-2.
StudyRisk of BiasApplicability ConcernsDecision
Patient SelectionIndex TestReference StandardFlow and TimingPatient SelectionIndex TestReference Standard
Ahmed 2012 [23]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Alegret 2020 [29]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
An 2024 [76]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Bergeron 2020 [30]Diagnostics 15 02383 i001?Diagnostics 15 02383 i002Diagnostics 15 02383 i001Diagnostics 15 02383 i002Diagnostics 15 02383 i001Diagnostics 15 02383 i002excluded
Boz 2020 [31]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Cabinio 2020 [32]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Cerino 2021 [33]??Diagnostics 15 02383 i001?Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001excluded
Cheah 2022 [34]?Diagnostics 15 02383 i001?Diagnostics 15 02383 i001?Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Chin 2020 [35]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Curiel 2016 [36]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Freedman 2018 [37]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Fukui 2015 [38]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Garre-Olmo 2017 [28]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001?Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Gielis 2021 [39]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Groppell 2019 [40]?Diagnostics 15 02383 i001Diagnostics 15 02383 i002Diagnostics 15 02383 i001?Diagnostics 15 02383 i001Diagnostics 15 02383 i002excluded
Inoue 2005 [18]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Isernia 2021 [41]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Ishikawa 2019 [27]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Ishiwata 2014 [42]Diagnostics 15 02383 i002Diagnostics 15 02383 i002Diagnostics 15 02383 i002Diagnostics 15 02383 i002Diagnostics 15 02383 i002Diagnostics 15 02383 i001Diagnostics 15 02383 i001excluded
Kobayashi 2022 [43]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Kubota 2017 [20]?Diagnostics 15 02383 i001NADiagnostics 15 02383 i001Diagnostics 15 02383 i002Diagnostics 15 02383 i001NAincluded
Li 2024 [74]?Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Li 2025 [77]?Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001?included
Li 2023 [44]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Li 2022 [26]Diagnostics 15 02383 i001Diagnostics 15 02383 i001?Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Li 2023 [45]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Libon 2024 [19]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001?included
Liu 2023 [73]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Memória 2014 [46]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Morisson 2016 [70]???????excluded
Müller 2019 [47]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Müller 2017 [48]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Mychajliw 2024 [79]Diagnostics 15 02383 i001Diagnostics 15 02383 i001???Diagnostics 15 02383 i001?excluded
Na 2023 [49]?Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001?Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Noguchi-Shinohara 2020 [50]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Park 2018 [51]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001?Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Porrselvi 2022 [25]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Possin 2018 [52]??Diagnostics 15 02383 i001?Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001excluded
Rigby 2024 [78]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Robens 2019 [53]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Rodríguez-Salgado 2021 [54]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Satler 2015 [55]?Diagnostics 15 02383 i001Diagnostics 15 02383 i002?Diagnostics 15 02383 i002Diagnostics 15 02383 i001?excluded
Saxton 2009 [21]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Scharre 2017 [56]Diagnostics 15 02383 i002Diagnostics 15 02383 i001Diagnostics 15 02383 i002Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001excluded
Shigemori 2015 [57]Diagnostics 15 02383 i002Diagnostics 15 02383 i002??Diagnostics 15 02383 i002Diagnostics 15 02383 i002?excluded
Simfukwe 2022 [22]Diagnostics 15 02383 i001Diagnostics 15 02383 i001?Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Sloane 2022 [58]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Suzumura 2018 [59]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Tamura 2006 [60]?Diagnostics 15 02383 i001??Diagnostics 15 02383 i001Diagnostics 15 02383 i002Diagnostics 15 02383 i001excluded
Um Din 2024 [72]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Wang 2023 [24]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Wilks 2021 [61]?Diagnostics 15 02383 i001Diagnostics 15 02383 i002?Diagnostics 15 02383 i001??excluded
Wong 2017 [62]Diagnostics 15 02383 i002Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i002Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Wu 2023 [63]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Wu 2017 [64]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Yamada 2022 [65]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Ye 2022 [66]Diagnostics 15 02383 i001Diagnostics 15 02383 i001?Diagnostics 15 02383 i002Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i002included
Yu 2019 [71]Diagnostics 15 02383 i001?Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001?Diagnostics 15 02383 i001included
Zhao 2019 [67]????Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001excluded
Zhang 2024 [75]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Zygouris 2015 [68]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Zygouris 2020 [69]Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001Diagnostics 15 02383 i001included
Diagnostics 15 02383 i001 Low Risk; Diagnostics 15 02383 i002 High Risk; ? Unclear Risk.
Figure A2. Analysis of sensitivity and specificity for the diagnosis of mild cognitive disorders by test duration [18,21,23,28,29,31,35,36,37,41,46,48,50,51,53,54,62,63,64,66,68,69,72,74,75,76].
Figure A2. Analysis of sensitivity and specificity for the diagnosis of mild cognitive disorders by test duration [18,21,23,28,29,31,35,36,37,41,46,48,50,51,53,54,62,63,64,66,68,69,72,74,75,76].
Diagnostics 15 02383 g0a2
Figure A3. Analysis of sensitivity and specificity for the diagnosis of mild cognitive disorders by modality of assessment [18,21,23,26,27,28,29,31,32,34,35,37,41,43,46,47,48,50,51,53,54,62,63,64,65,66,68,69,72,74,75,76].
Figure A3. Analysis of sensitivity and specificity for the diagnosis of mild cognitive disorders by modality of assessment [18,21,23,26,27,28,29,31,32,34,35,37,41,43,46,47,48,50,51,53,54,62,63,64,65,66,68,69,72,74,75,76].
Diagnostics 15 02383 g0a3
Figure A4. Analysis of sensitivity and specificity for the diagnosis of mild cognitive disorders by type of mobile device [18,21,23,26,27,28,29,31,34,35,37,38,43,47,48,50,51,53,54,62,63,64,65,66,68,69,72,74,75,76].
Figure A4. Analysis of sensitivity and specificity for the diagnosis of mild cognitive disorders by type of mobile device [18,21,23,26,27,28,29,31,34,35,37,38,43,47,48,50,51,53,54,62,63,64,65,66,68,69,72,74,75,76].
Diagnostics 15 02383 g0a4
Figure A5. Analysis of sensitivity and specificity for the diagnosis of mild cognitive disorders by type of touchscreen device [18,21,23,26,27,28,29,31,32,34,35,36,37,38,41,43,46,47,48,50,51,53,54,62,63,64,65,66,68,69,72,74,75,76].
Figure A5. Analysis of sensitivity and specificity for the diagnosis of mild cognitive disorders by type of touchscreen device [18,21,23,26,27,28,29,31,32,34,35,36,37,38,41,43,46,47,48,50,51,53,54,62,63,64,65,66,68,69,72,74,75,76].
Diagnostics 15 02383 g0a5

References

  1. Dubois, B.; Padovani, A.; Scheltens, P.; Rossi, A.; Dell’Agnello, G. Timely Diagnosis for Alzheimer’s Disease: A Literature Review on Benefits and Challenges. J. Alzheimers Dis. 2016, 49, 617–631. [Google Scholar] [CrossRef]
  2. Porsteinsson, A.P.; Isaacson, R.S.; Knox, S.; Sabbagh, M.N.; Rubino, I. Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 2021. J. Prev. Alzheimers Dis. 2021, 8, 371–386. [Google Scholar] [CrossRef] [PubMed]
  3. Stokin, G.B.; Krell-Roesch, J.; Petersen, R.C.; Geda, Y.E. Mild Neurocognitive Disorder: An Old Wine in a New Bottle. Harv. Rev. Psychiatry 2015, 23, 368–376. [Google Scholar] [CrossRef] [PubMed]
  4. Jongsiriyanyong, S.; Limpawattana, P. Mild Cognitive Impairment in Clinical Practice: A Review Article. Am. J. Alzheimers Dis. Other Demen. 2018, 33, 500–507. [Google Scholar] [CrossRef] [PubMed]
  5. Sanford, A.M. Mild Cognitive Impairment. Clin. Geriatr. Med. 2017, 33, 325–337. [Google Scholar] [CrossRef]
  6. Wood, E.; Willoughby, T.; Rushing, A.; Bechtel, L.; Gilbert, J. Use of Computer Input Devices by Older Adults. J. Appl. Gerontol. 2005, 24, 419–438. [Google Scholar] [CrossRef]
  7. Sachs-Ericsson, N.; Blazer, D.G. The New DSM-5 Diagnosis of Mild Neurocognitive Disorder and Its Relation to Research in Mild Cognitive Impairment. Aging Ment. Health 2015, 19, 2–12. [Google Scholar] [CrossRef]
  8. Folstein, M.F.; Folstein, S.E.; McHugh, P.R. “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12, 189–198. [Google Scholar] [CrossRef]
  9. Nasreddine, Z.S.; Phillips, N.A.; Bédirian, V.; Charbonneau, S.; Whitehead, V.; Collin, I.; Cummings, J.L.; Chertkow, H. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 2005, 53, 695–699. [Google Scholar] [CrossRef]
  10. Pinto, T.C.C.; Machado, L.; Bulgacov, T.M.; Rodrigues-Júnior, A.L.; Costa, M.L.G.; Ximenes, R.C.C.; Sougey, E.B. Is the Montreal Cognitive Assessment (MoCA) Screening Superior to the Mini-Mental State Examination (MMSE) in the Detection of Mild Cognitive Impairment (MCI) and Alzheimer’s Disease (AD) in the Elderly? Int Psychogeriatr 2019, 31, 491–504. [Google Scholar] [CrossRef]
  11. Chun, C.T.; Seward, K.; Patterson, A.; Melton, A.; MacDonald-Wicks, L. Evaluation of Available Cognitive Tools Used to Measure Mild Cognitive Decline: A Scoping Review. Nutrients 2021, 13, 3974. [Google Scholar] [CrossRef]
  12. Breton, A.; Casey, D.; Arnaoutoglou, N.A. Cognitive Tests for the Detection of Mild Cognitive Impairment (MCI), the Prodromal Stage of Dementia: Meta-Analysis of Diagnostic Accuracy Studies. Int. J. Geriatr. Psychiatry 2019, 34, 233–242. [Google Scholar] [CrossRef]
  13. Giaquinto, F.; Battista, P.; Angelelli, P. Touchscreen Cognitive Tools for Mild Cognitive Impairment and Dementia Used in Primary Care Across Diverse Cultural and Literacy Populations: A Systematic Review. J. Alzheimers Dis. 2022, 90, 1359–1380. [Google Scholar] [CrossRef] [PubMed]
  14. Um Din, N.; Maronnat, F.; Zolnowski-Kolp, V.; Otmane, S.; Belmin, J. Diagnosis Accuracy of Touchscreen-Based Testings for Major Neurocognitive Disorders: A Systematic Review and Meta-Analysis. Age Ageing 2025, 54, afaf204. [Google Scholar] [CrossRef] [PubMed]
  15. Salameh, J.-P.; Bossuyt, P.M.; McGrath, T.A.; Thombs, B.D.; Hyde, C.J.; Macaskill, P.; Deeks, J.J.; Leeflang, M.; Korevaar, D.A.; Whiting, P.; et al. Preferred Reporting Items for Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies (PRISMA-DTA): Explanation, Elaboration, and Checklist. BMJ 2020, 370, m2632. [Google Scholar] [CrossRef] [PubMed]
  16. Whiting, P.F.; Rutjes, A.W.S.; Westwood, M.E.; Mallett, S.; Deeks, J.J.; Reitsma, J.B.; Leeflang, M.M.G.; Sterne, J.A.C.; Bossuyt, P.M.M. QUADAS-2 Group QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. Ann. Intern. Med. 2011, 155, 529–536. [Google Scholar] [CrossRef]
  17. Nyaga, V.N.; Arbyn, M. Metadta: A Stata Command for Meta-Analysis and Meta-Regression of Diagnostic Test Accuracy Data—A Tutorial. Arch. Public Health 2022, 80, 95. [Google Scholar] [CrossRef]
  18. Inoue, M.; Urakami, K.; Taniguchi, M.; Kimura, Y.; Saito, J.; Nakashima, K. Evaluation of a Computerized Test System to Screen for Mild Cognitive Impairment. Psychogeriatrics 2005, 5, 36–41. [Google Scholar] [CrossRef]
  19. Libon, D.J.; Swenson, R.; Price, C.C.; Lamar, M.; Cosentino, S.; Bezdicek, O.; Kling, M.A.; Tobyne, S.; Jannati, A.; Banks, R.; et al. Digital Assessment of Cognition in Neurodegenerative Disease: A Data Driven Approach Leveraging Artificial Intelligence. Front. Psychol. 2024, 15, 1415629. [Google Scholar] [CrossRef]
  20. Kubota, Y.; Yamaguchi, T.; Maeta, T.; Okada, Y.; Miura, Y.; Martono, N.P.; Ohwada, H.; Tania, G. Feature Extraction Based on Touch Interaction Data in Virtual Reality-Based IADL for Characterization of Mild Cognitive Impairment. In Proceedings of the 12th International Joint Conference on Computer Vision, Imaging and Computer Graphics Theory and Applications, Porto, Portugal, 27 February–1 March 2017; pp. 152–157. [Google Scholar] [CrossRef]
  21. Saxton, J.; Morrow, L.; Eschman, A.; Archer, G.; Luther, J.; Zuccolotto, A. Computer Assessment of Mild Cognitive Impairment. Postgrad. Med. 2009, 121, 177–185. [Google Scholar] [CrossRef]
  22. Simfukwe, C.; Youn, Y.C.; Kim, S.Y.; An, S.S. Digital Trail Making Test-Black and White: Normal vs MCI. Appl. Neuropsychol. Adult 2022, 29, 1296–1303. [Google Scholar] [CrossRef]
  23. Ahmed, S.; de Jager, C.; Wilcock, G. A Comparison of Screening Tools for the Assessment of Mild Cognitive Impairment: Preliminary Findings. Neurocase 2012, 18, 336–351. [Google Scholar] [CrossRef]
  24. Wang, Y.; Chen, T.; Wang, C.; Ogihara, A.; Ma, X.; Huang, S.; Zhou, S.; Li, S.; Liu, J.; Li, K. A New Smart 2-Min Mobile Alerting Method for Mild Cognitive Impairment Due to Alzheimer’s Disease in the Community. Brain Sci. 2023, 13, 244. [Google Scholar] [CrossRef] [PubMed]
  25. Porrselvi, A.P. TAM Battery: Development and Pilot Testing of a Tamil Computer-Assisted Cognitive Test Battery for Older Adults. Clin. Neuropsychol. 2023, 37, 1005–1024. [Google Scholar] [CrossRef]
  26. Li, J.; Yang, J.; Yang, J.; Yang, H.; Lan, M.; Gao, L. Characterizing Cognitive Impairment through Drawing Features Extracted from the Tree Drawing Test. In Proceedings of the 2022 7th International Conference on Intelligent Informatics and Biomedical Science (ICIIBMS), Nara, Japan, 24–26 November 2022; Volume 7, pp. 341–347. [Google Scholar]
  27. Ishikawa, T.; Nemoto, M.; Nemoto, K.; Takeuchi, T.; Numata, Y.; Watanabe, R.; Tsukada, E.; Ota, M.; Higashi, S.; Arai, T.; et al. Handwriting Features of Multiple Drawing Tests for Early Detection of Alzheimer’s Disease: A Preliminary Result. Stud. Health Technol. Inform. 2019, 264, 168–172. [Google Scholar] [CrossRef] [PubMed]
  28. Garre-Olmo, J.; Faúndez-Zanuy, M.; López-de-Ipiña, K.; Calvó-Perxas, L.; Turró-Garriga, O. Kinematic and Pressure Features of Handwriting and Drawing: Preliminary Results Between Patients with Mild Cognitive Impairment, Alzheimer Disease and Healthy Controls. Curr. Alzheimer Res. 2017, 14, 960–968. [Google Scholar] [CrossRef]
  29. Alegret, M.; Muñoz, N.; Roberto, N.; Rentz, D.M.; Valero, S.; Gil, S.; Marquié, M.; Hernández, I.; Riveros, C.; Sanabria, A.; et al. A Computerized Version of the Short Form of the Face-Name Associative Memory Exam (FACEmemory®) for the Early Detection of Alzheimer’s Disease. Alzheimers Res. Ther. 2020, 12, 25. [Google Scholar] [CrossRef]
  30. Bergeron, M.F.; Landset, S.; Zhou, X.; Ding, T.; Khoshgoftaar, T.M.; Zhao, F.; Du, B.; Chen, X.; Wang, X.; Zhong, L.; et al. Utility of MemTrax and Machine Learning Modeling in Classification of Mild Cognitive Impairment. J. Alzheimers Dis. 2020, 77, 1545–1558. [Google Scholar] [CrossRef]
  31. Eraslan Boz, H.; Limoncu, H.; Zygouris, S.; Tsolaki, M.; Giakoumis, D.; Votis, K.; Tzovaras, D.; Öztürk, V.; Yener, G.G. A New Tool to Assess Amnestic Mild Cognitive Impairment in Turkish Older Adults: Virtual Supermarket (VSM). Neuropsychol. Dev. Cogn. B Aging Neuropsychol. Cogn. 2020, 27, 639–653. [Google Scholar] [CrossRef]
  32. Cabinio, M.; Rossetto, F.; Isernia, S.; Saibene, F.L.; Di Cesare, M.; Borgnis, F.; Pazzi, S.; Migliazza, T.; Alberoni, M.; Blasi, V.; et al. The Use of a Virtual Reality Platform for the Assessment of the Memory Decline and the Hippocampal Neural Injury in Subjects with Mild Cognitive Impairment: The Validity of Smart Aging Serious Game (SASG). J. Clin. Med. 2020, 9, 1355. [Google Scholar] [CrossRef]
  33. Cerino, E.S.; Katz, M.J.; Wang, C.; Qin, J.; Gao, Q.; Hyun, J.; Hakun, J.G.; Roque, N.A.; Derby, C.A.; Lipton, R.B.; et al. Variability in Cognitive Performance on Mobile Devices Is Sensitive to Mild Cognitive Impairment: Results from the Einstein Aging Study. Front. Digit. Health 2021, 3, 758031. [Google Scholar] [CrossRef]
  34. Cheah, W.-T.; Hwang, J.-J.; Hong, S.-Y.; Fu, L.-C.; Chang, Y.-L.; Chen, T.-F.; Chen, I.-A.; Chou, C.-C. A Digital Screening System for Alzheimer Disease Based on a Neuropsychological Test and a Convolutional Neural Network: System Development and Validation. JMIR Med. Inform. 2022, 10, e31106. [Google Scholar] [CrossRef]
  35. Chin, J.; Kim, D.E.; Lee, H.; Yun, J.; Lee, B.H.; Park, J.; Yeom, J.; Shin, D.S.; Na, D.L. A Validation Study of the Inbrain CST: A Tablet Computer-Based Cognitive Screening Test for Elderly People with Cognitive Impairment. J. Korean Med. Sci. 2020, 35, e292. [Google Scholar] [CrossRef]
  36. Curiel, R.E.; Crocco, E.; Rosado, M.; Duara, R.; Greig, M.T.; Raffo, A.; Loewenstein, D.A. A Brief Computerized Paired Associate Test for the Detection of Mild Cognitive Impairment in Community-Dwelling Older Adults. J. Alzheimers Dis. 2016, 54, 793–799. [Google Scholar] [CrossRef] [PubMed]
  37. Freedman, M.; Leach, L.; Carmela Tartaglia, M.; Stokes, K.A.; Goldberg, Y.; Spring, R.; Nourhaghighi, N.; Gee, T.; Strother, S.C.; Alhaj, M.O.; et al. The Toronto Cognitive Assessment (TorCA): Normative Data and Validation to Detect Amnestic Mild Cognitive Impairment. Alzheimers Res. Ther. 2018, 10, 65. [Google Scholar] [CrossRef] [PubMed]
  38. Fukui, Y.; Yamashita, T.; Hishikawa, N.; Kurata, T.; Sato, K.; Omote, Y.; Kono, S.; Yunoki, T.; Kawahara, Y.; Hatanaka, N.; et al. Computerized Touch-Panel Screening Tests for Detecting Mild Cognitive Impairment and Alzheimer’s Disease. Intern. Med. 2015, 54, 895–902. [Google Scholar] [CrossRef] [PubMed]
  39. Gielis, K.; Vanden Abeele, M.-E.; Verbert, K.; Tournoy, J.; De Vos, M.; Vanden Abeele, V. Detecting Mild Cognitive Impairment via Digital Biomarkers of Cognitive Performance Found in Klondike Solitaire: A Machine-Learning Study. Digit. Biomark. 2021, 5, 44–52. [Google Scholar] [CrossRef]
  40. Groppell, S.; Soto-Ruiz, K.M.; Flores, B.; Dawkins, W.; Smith, I.; Eagleman, D.M.; Katz, Y. A Rapid, Mobile Neurocognitive Screening Test to Aid in Identifying Cognitive Impairment and Dementia (BrainCheck): Cohort Study. JMIR Aging 2019, 2, e12615. [Google Scholar] [CrossRef]
  41. Isernia, S.; Cabinio, M.; Di Tella, S.; Pazzi, S.; Vannetti, F.; Gerli, F.; Mosca, I.E.; Lombardi, G.; Macchi, C.; Sorbi, S.; et al. Diagnostic Validity of the Smart Aging Serious Game: An Innovative Tool for Digital Phenotyping of Mild Neurocognitive Disorder. J. Alzheimers Dis. 2021, 83, 1789–1801. [Google Scholar] [CrossRef]
  42. Ishiwata, A.; Kitamura, S.; Nomura, T.; Nemoto, R.; Ishii, C.; Wakamatsu, N.; Katayama, Y. Early Identification of Cognitive Impairment and Dementia: Results from Four Years of the Community Consultation Center. Arch. Gerontol. Geriatr. 2014, 59, 457–461. [Google Scholar] [CrossRef]
  43. Kobayashi, M.; Yamada, Y.; Shinkawa, K.; Nemoto, M.; Nemoto, K.; Arai, T. Automated Early Detection of Alzheimer’s Disease by Capturing Impairments in Multiple Cognitive Domains with Multiple Drawing Tasks. J. Alzheimers Dis. 2022, 88, 1075–1089. [Google Scholar] [CrossRef]
  44. Li, A.; Li, J.; Zhang, D.; Wu, W.; Zhao, J.; Qiang, Y. Synergy through Integration of Digital Cognitive Tests and Wearable Devices for Mild Cognitive Impairment Screening. Front. Hum. Neurosci. 2023, 17, 1183457. [Google Scholar] [CrossRef]
  45. Li, K.; Ma, X.; Chen, T.; Xin, J.; Wang, C.; Wu, B.; Ogihara, A.; Zhou, S.; Liu, J.; Huang, S.; et al. A New Early Warning Method for Mild Cognitive Impairment Due to Alzheimer’s Disease Based on Dynamic Evaluation of the “Spatial Executive Process”. Digit. Health 2023, 9, 20552076231194938. [Google Scholar] [CrossRef]
  46. Memória, C.M.; Yassuda, M.S.; Nakano, E.Y.; Forlenza, O.V. Contributions of the Computer-Administered Neuropsychological Screen for Mild Cognitive Impairment (CANS-MCI) for the Diagnosis of MCI in Brazil. Int. Psychogeriatr. 2014, 26, 1483–1491. [Google Scholar] [CrossRef] [PubMed]
  47. Müller, S.; Herde, L.; Preische, O.; Zeller, A.; Heymann, P.; Robens, S.; Elbing, U.; Laske, C. Diagnostic Value of Digital Clock Drawing Test in Comparison with CERAD Neuropsychological Battery Total Score for Discrimination of Patients in the Early Course of Alzheimer’s Disease from Healthy Individuals. Sci. Rep. 2019, 9, 3543. [Google Scholar] [CrossRef] [PubMed]
  48. Müller, S.; Preische, O.; Heymann, P.; Elbing, U.; Laske, C. Diagnostic Value of a Tablet-Based Drawing Task for Discrimination of Patients in the Early Course of Alzheimer’s Disease from Healthy Individuals. J. Alzheimers Dis. 2017, 55, 1463–1469. [Google Scholar] [CrossRef] [PubMed]
  49. Na, S.; Seo, S.W.; Kim, Y.J.; Yoo, H.; Lee, E.-S. Correlation Analysis between Subtest Scores of CERAD-K and a Newly Developed Tablet Computer-Based Digital Cognitive Test (Inbrain CST). Front. Aging Neurosci. 2023, 15, 1178324. [Google Scholar] [CrossRef]
  50. Noguchi-Shinohara, M.; Domoto, C.; Yoshida, T.; Niwa, K.; Yuki-Nozaki, S.; Samuraki-Yokohama, M.; Sakai, K.; Hamaguchi, T.; Ono, K.; Iwasa, K.; et al. A New Computerized Assessment Battery for Cognition (C-ABC) to Detect Mild Cognitive Impairment and Dementia around 5 Min. PLoS ONE 2020, 15, e0243469. [Google Scholar] [CrossRef]
  51. Park, J.-H.; Jung, M.; Kim, J.; Park, H.Y.; Kim, J.-R.; Park, J.-H. Validity of a Novel Computerized Screening Test System for Mild Cognitive Impairment. Int. Psychogeriatr. 2018, 30, 1455–1463. [Google Scholar] [CrossRef]
  52. Possin, K.; Moskowitz, T.; Erlhoff, S.; Rogers, K.; Johnson, E.; Steele, N.; Higgins, J.; Stiver, J.; Alioto, A.; Farias, S.; et al. The Brain Health Assessment for Detecting and Diagnosing Neurocognitive Disorders. J. Am. Geriatr. Soc. 2018, 66, 150–156. [Google Scholar] [CrossRef]
  53. Robens, S.; Heymann, P.; Gienger, R.; Hett, A.; Müller, S.; Laske, C.; Loy, R.; Ostermann, T.; Elbing, U. The Digital Tree Drawing Test for Screening of Early Dementia: An Explorative Study Comparing Healthy Controls, Patients with Mild Cognitive Impairment, and Patients with Early Dementia of the Alzheimer Type. J. Alzheimers Dis. 2019, 68, 1561–1574. [Google Scholar] [CrossRef]
  54. Rodríguez-Salgado, A.M.; Llibre-Guerra, J.J.; Tsoy, E.; Peñalver-Guia, A.I.; Bringas, G.; Erlhoff, S.J.; Kramer, J.H.; Allen, I.E.; Valcour, V.; Miller, B.L.; et al. A Brief Digital Cognitive Assessment for Detection of Cognitive Impairment in Cuban Older Adults. J. Alzheimers Dis. 2021, 79, 85–94. [Google Scholar] [CrossRef] [PubMed]
  55. Satler, C.; Beham, F.; Garcias, A.; Tomaz, C.; Tavares, M. Computerized Spatial Delayed Recognition Span Task: A Specific Tool to Assess Visuospatial Working Memory. Front. Aging Neurosci. 2015, 7, 53. [Google Scholar] [CrossRef] [PubMed]
  56. Scharre, D.W.; Chang, S.I.; Nagaraja, H.N.; Vrettos, N.E.; Bornstein, R.A. Digitally Translated Self-Administered Gerocognitive Examination (eSAGE): Relationship with Its Validated Paper Version, Neuropsychological Evaluations, and Clinical Assessments. Alzheimers Res. Ther. 2017, 9, 44. [Google Scholar] [CrossRef]
  57. Shigemori, T.; Harbi, Z.; Kawanaka, H.; Hicks, Y.; Setchi, R.; Takase, H.; Tsuruoka, S. Feature Extraction Method for Clock Drawing Test; Ding, L., Pang, C., Kew, L., Jain, L., Howlett, R., Eds.; Elsevier: Amsterdam, The Netherlands, 2015; Volume 60, pp. 1707–1714. [Google Scholar]
  58. Sloane, K.L.; Mefford, J.A.; Zhao, Z.; Xu, M.; Zhou, G.; Fabian, R.; Wright, A.E.; Glenn, S. Validation of a Mobile, Sensor-Based Neurobehavioral Assessment with Digital Signal Processing and Machine-Learning Analytics. Cogn. Behav. Neurol. 2022, 35, 169–178. [Google Scholar] [CrossRef] [PubMed]
  59. Suzumura, S.; Osawa, A.; Maeda, N.; Sano, Y.; Kandori, A.; Mizuguchi, T.; Yin, Y.; Kondo, I. Differences among Patients with Alzheimer’s Disease, Older Adults with Mild Cognitive Impairment and Healthy Older Adults in Finger Dexterity. Geriatr. Gerontol. Int. 2018, 18, 907–914. [Google Scholar] [CrossRef]
  60. Tamura, T.; Tshji, M.; Higashi, Y.; Sekine, M.; Kohdabashi, A.; Fujimoto, T.; Mitsuyama, M. New Computer-Based Cognitive Function Test for the Elderly. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2006, 1, 692–694. [Google Scholar]
  61. Wilks, H.; Aschenbrenner, A.; Gordon, B.; Balota, D.; Fagan, A.; Musiek, E.; Balls-Berry, J.; Benzinger, T.; Cruchaga, C.; Morris, J.; et al. Sharper in the Morning: Cognitive Time of Day Effects Revealed with High-Frequency Smartphone Testing. J. Clin. Exp. Neuropsychol. 2021, 43, 825–837. [Google Scholar] [CrossRef]
  62. Wong, A.; Fong, C.-H.; Mok, V.C.-T.; Leung, K.-T.; Tong, R.K.-Y. Computerized Cognitive Screen (CoCoSc): A Self-Administered Computerized Test for Screening for Cognitive Impairment in Community Social Centers. J. Alzheimers Dis. 2017, 59, 1299–1306. [Google Scholar] [CrossRef]
  63. Wu, J.; Tu, J.; Liu, Z.; Cao, L.; He, Y.; Huang, J.; Tao, J.; Wong, M.N.K.; Chen, L.; Lee, T.M.C.; et al. An Effective Test (EOmciSS) for Screening Older Adults with Mild Cognitive Impairment in a Community Setting: Development and Validation Study. J. Med. Internet Res. 2023, 25, e40858. [Google Scholar] [CrossRef]
  64. Wu, Y.-H.; Vidal, J.-S.; de Rotrou, J.; Sikkes, S.A.M.; Rigaud, A.-S.; Plichart, M. Can a Tablet-Based Cancellation Test Identify Cognitive Impairment in Older Adults? PLoS ONE 2017, 12, e0181809. [Google Scholar] [CrossRef] [PubMed]
  65. Yamada, Y.; Kobayashi, M.; Shinkawa, K.; Nemoto, M.; Ota, M.; Nemoto, K.; Arai, T. Automated Analysis of Drawing Process for Detecting Prodromal and Clinical Dementia. In Proceedings of the 2022 IEEE International Conference on Digital Health (ICDH), Barcelona, Spain, 11–15 July 2022; pp. 1–6. [Google Scholar]
  66. Ye, S.; Sun, K.; Huynh, D.; Phi, H.Q.; Ko, B.; Huang, B.; Hosseini Ghomi, R. A Computerized Cognitive Test Battery for Detection of Dementia and Mild Cognitive Impairment: Instrument Validation Study. JMIR Aging 2022, 5, e36825. [Google Scholar] [CrossRef] [PubMed]
  67. Zhao, K.; Yoshizumi, T.; Ota, M.; Ekoyama, S.; Arai, T. Development of Cognitive Level Estimation Model Using Mobile Applications. Alzheimer’s Dement. 2019, 15, 957–958. [Google Scholar] [CrossRef]
  68. Zygouris, S.; Giakoumis, D.; Votis, K.; Doumpoulakis, S.; Ntovas, K.; Segkouli, S.; Karagiannidis, C.; Tzovaras, D.; Tsolaki, M. Can a Virtual Reality Cognitive Training Application Fulfill a Dual Role? Using the Virtual Supermarket Cognitive Training Application as a Screening Tool for Mild Cognitive Impairment. J. Alzheimers Dis. 2015, 44, 1333–1347. [Google Scholar] [CrossRef]
  69. Zygouris, S.; Iliadou, P.; Lazarou, E.; Giakoumis, D.; Votis, K.; Alexiadis, A.; Triantafyllidis, A.; Segkouli, S.; Tzovaras, D.; Tsiatsos, T.; et al. Detection of Mild Cognitive Impairment in an At-Risk Group of Older Adults: Can a Novel Self-Administered Serious Game-Based Screening Test Improve Diagnostic Accuracy? J. Alzheimers Dis. 2020, 78, 405–412. [Google Scholar] [CrossRef]
  70. Morrison, R.; Pei, H.; Novak, G.; Kaufer, D.; Welsh-Bohmer, K.; Ruhmel, S.; Narayan, V.A. Validation of a Novel Computerized Selfadministered Memory-Screening Test with Automated Reporting (SAMSTAR) in Patients with Mild Cognitive Impairment and Normal Control Participants: A Randomized, Crossover, Controlled Study. Neuropsychopharmacology 2016, 41, S345–S346. [Google Scholar] [CrossRef]
  71. Yu, N.-Y.; Chang, S.-H. Characterization of the Fine Motor Problems in Patients with Cognitive Dysfunction—A Computerized Handwriting Analysis. Hum. Mov. Sci. 2019, 65, 71–79. [Google Scholar] [CrossRef]
  72. Um Din, N.; Maronnat, F.; Pariel, S.; Badra, F.; Belmin, J. A Digital Clock Drawing Test on Tablet for the Diagnosis of Neurocognitive Disorders in Older Adults. Stud. Health Technol. Inform. 2024, 316, 1878–1882. [Google Scholar] [CrossRef]
  73. Liu, L.-Y.; Xing, Y.; Zhang, Z.-H.; Zhang, Q.-G.; Dong, M.; Wang, H.; Cai, L.; Wang, X.; Tang, Y. Validation of a Computerized Cognitive Training Tool to Assess Cognitive Impairment and Enable Differentiation Between Mild Cognitive Impairment and Dementia. J. Alzheimers Dis. 2023, 96, 93–101. [Google Scholar] [CrossRef]
  74. Li, A.; Li, J.; Chai, J.; Wu, W.; Chaudhary, S.; Zhao, J.; Qiang, Y. Detection of Mild Cognitive Impairment Through Hand Motor Function Under Digital Cognitive Test: Mixed Methods Study. JMIR Mhealth Uhealth 2024, 12, e48777. [Google Scholar] [CrossRef]
  75. Zhang, X.; Lv, L.; Shen, J.; Chen, J.; Zhang, H.; Li, Y. A Tablet-Based Multi-Dimensional Drawing System Can Effectively Distinguish Patients with Amnestic MCI from Healthy Individuals. Sci. Rep. 2024, 14, 982. [Google Scholar] [CrossRef]
  76. An, D.; Shin, J.S.; Bae, N.; Seo, S.W.; Na, D.L. Validity of the Tablet-Based Digital Cognitive Test (SCST) in Identifying Different Degrees of Cognitive Impairment. J. Korean Med. Sci. 2024, 39, e247. [Google Scholar] [CrossRef]
  77. Li, A.; Xue, C.; Wu, R.; Wu, W.; Zhao, J.; Qiang, Y. Unearthing Subtle Cognitive Variations: A Digital Screening Tool for Detecting and Monitoring Mild Cognitive Impairment. Int. J. Hum. Comput. Interact. 2025, 41, 2579–2599. [Google Scholar] [CrossRef]
  78. Rigby, T.; Gregoire, A.M.; Reader, J.; Kahsay, Y.; Fisher, J.; Kairys, A.; Bhaumik, A.K.; Rahman-Filipiak, A.; Maher, A.C.; Hampstead, B.M.; et al. Identification of Amnestic Mild Cognitive Impairment among Black and White Community-Dwelling Older Adults Using NIH Toolbox Cognition Tablet Battery. J. Int. Neuropsychol. Soc. 2024, 30, 689–696. [Google Scholar] [CrossRef] [PubMed]
  79. Mychajliw, C.; Holz, H.; Minuth, N.; Dawidowsky, K.; Eschweiler, G.W.; Metzger, F.G.; Wortha, F. Performance Differences of a Touch-Based Serial Reaction Time Task in Healthy Older Participants and Older Participants with Cognitive Impairment on a Tablet: Experimental Study. JMIR Aging 2024, 7, e48265. [Google Scholar] [CrossRef] [PubMed]
  80. Park, J.-H. Discriminant Power of Smartphone-Derived Keystroke Dynamics for Mild Cognitive Impairment Compared to a Neuropsychological Screening Test: Cross-Sectional Study. J. Med. Internet Res. 2024, 26, e59247. [Google Scholar] [CrossRef] [PubMed]
  81. Thompson, L.I.; Kunicki, Z.J.; Emrani, S.; Strenger, J.; De Vito, A.N.; Britton, K.J.; Dion, C.; Harrington, K.D.; Roque, N.; Salloway, S.; et al. Remote and In-Clinic Digital Cognitive Screening Tools Outperform the MoCA to Distinguish Cerebral Amyloid Status among Cognitively Healthy Older Adults. Alzheimers Dement. 2023, 15, e12500. [Google Scholar] [CrossRef]
  82. Nurgalieva, L.; Jara Laconich, J.J.; Baez, M.; Casati, F.; Marchese, M. A Systematic Literature Review of Research-Derived Touchscreen Design Guidelines for Older Adults. IEEE Access 2019, 7, 22035–22058. [Google Scholar] [CrossRef]
  83. McInnes, M.D.; Moher, D.; Thombs, B.D.; McGrath, T.A.; Bossuyt, P.M.; Clifford, T.; Cohen, J.F.; Deeks, J.J.; Gatsonis, C.; Hooft, L.; et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: The PRISMA-DTA statement. JAMA 2018, 319, 388–396. [Google Scholar] [CrossRef]
  84. Berron, D.; Glanz, W.; Clark, L.; Basche, K.; Grande, X.; Güsten, J.; Billette, O.V.; Hempen, I.; Naveed, M.H.; Diersch, N.; et al. A Remote Digital Memory Composite to Detect Cognitive Impairment in Memory Clinic Samples in Unsupervised Settings Using Mobile Devices. npj Digit. Med. 2024, 7, 79. [Google Scholar] [CrossRef]
Figure 1. Flow chart of the studies included.
Figure 1. Flow chart of the studies included.
Diagnostics 15 02383 g001
Figure 2. Analysis of sensitivity and specificity for the diagnosis of mild cognitive disorders [18,21,23,26,27,28,29,31,32,34,35,36,37,38,41,43,46,47,48,50,51,53,54,62,63,64,65,66,68,69,72,74,75,76].
Figure 2. Analysis of sensitivity and specificity for the diagnosis of mild cognitive disorders [18,21,23,26,27,28,29,31,32,34,35,36,37,38,41,43,46,47,48,50,51,53,54,62,63,64,65,66,68,69,72,74,75,76].
Diagnostics 15 02383 g002
Figure 3. Summary ROC curve of sensitivity and specificity for the diagnosis of mild cognitive disorders.
Figure 3. Summary ROC curve of sensitivity and specificity for the diagnosis of mild cognitive disorders.
Diagnostics 15 02383 g003
Figure 4. Subgroup analysis of pooled sensitivity and specificity of touchscreen cognitive tests for the diagnosis of mild cognitive disorders.
Figure 4. Subgroup analysis of pooled sensitivity and specificity of touchscreen cognitive tests for the diagnosis of mild cognitive disorders.
Diagnostics 15 02383 g004
Table 1. Cognitive tests with the highest pooled sensitivity and specificity.
Table 1. Cognitive tests with the highest pooled sensitivity and specificity.
Authors YearCognitive TestingsDuration (min)Administration ModeCognitive Domains AssessedDiagnostic Performance
An 2024 [76]Seoul Digital Cognitive Test30NSAttention, language, visuospatial function, memory, executive functionse: 0.81
spe: 0.89
Cheah 2022 [34]Rey-Osterrieth Complex Figure-Assessor-administeredVisuospatial constructional capabilities and visual memory function (immediate and recall), copyingse: 0.85
spe: 0.91
Curiel 2016 [36]Miami Test of Semantic Interference and Learning8–10NSSemantic memory, categorizationse: 0.85
spe: 0.84
Garre-Olmo 2017 [28]7 tasks: figure copying (simple spiral, 3D house, crossed pentagons), clock drawing test, sentence copying, writing a dictated sentence and a spontaneous sentence10–15Assessor-administeredKinesthetic, visuospatial function, motor featuresFor the task writing a dictated sentence:
se: 1.00
spe: 1.00
Li 2024 [74]Drawing and Dragging Tasks15Self-administeredOrientation, selective and sustained attention, visual memory and reconstruction, visuospatial organization, and hand motor skillsse: 0.86
spe: 0.91
Park 2018 [51]Mobile cognitive function test system for screening mild cognitive impairment10Assessor-administeredMemory, orientation, attention, visuospatial ability, language, executive function, reaction timese: 0.99
spe: 0.93
Rodrigues-Salgado 2021 [54]Brain Health Assessment10Assessor-administeredMemory, processing speed and executive function, visuospatial ability, languagese: 0.87
spe: 0.85
Saxton 2009 [21]Computer Assessment of Mild Cognitive Impairment20Self-administeredVerbal and visual memory, attention, psychomotor speed, language, spatial and executive functioningse: 0.86
spe: 0.94
Wu 2023 [63]Efficient Online MCI Screening System10Self-administeredMemory, visual attention, flexibility, visuospatial and executive function, cognitive proceeding speedse: 0.85
spe: 0.85
NS: Not specified.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Um Din, N.; Maronnat, F.; Oquendo, B.; Pariel, S.; Lafuente-Lafuente, C.; Badra, F.; Belmin, J. Diagnostic Accuracy of Touchscreen-Based Tests for Mild Cognitive Disorders: A Systematic Review and Meta-Analysis. Diagnostics 2025, 15, 2383. https://doi.org/10.3390/diagnostics15182383

AMA Style

Um Din N, Maronnat F, Oquendo B, Pariel S, Lafuente-Lafuente C, Badra F, Belmin J. Diagnostic Accuracy of Touchscreen-Based Tests for Mild Cognitive Disorders: A Systematic Review and Meta-Analysis. Diagnostics. 2025; 15(18):2383. https://doi.org/10.3390/diagnostics15182383

Chicago/Turabian Style

Um Din, Nathavy, Florian Maronnat, Bruno Oquendo, Sylvie Pariel, Carmelo Lafuente-Lafuente, Fadi Badra, and Joël Belmin. 2025. "Diagnostic Accuracy of Touchscreen-Based Tests for Mild Cognitive Disorders: A Systematic Review and Meta-Analysis" Diagnostics 15, no. 18: 2383. https://doi.org/10.3390/diagnostics15182383

APA Style

Um Din, N., Maronnat, F., Oquendo, B., Pariel, S., Lafuente-Lafuente, C., Badra, F., & Belmin, J. (2025). Diagnostic Accuracy of Touchscreen-Based Tests for Mild Cognitive Disorders: A Systematic Review and Meta-Analysis. Diagnostics, 15(18), 2383. https://doi.org/10.3390/diagnostics15182383

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop